naftifine
Trade name: naftin
Approved
Feb 29, 1988
Naftifine is a synthetic, broad spectrum, antifungal agent and allylamine derivative. The following in vitro data are available, but their clinical significance is unknown. Naftifine has been shown to exhibit fungicidal activity in vitro against a broad spectrum of organisms including Trichophyton rubrum, Trichophyton mentagrophytes, Trichophyton tonsurans, Epidermophyton floccosum, and Microsporum canis, Microsporum audouini, and Microsporum gypseum; and fungistatic activity against Candida species including Candida albicans. However it is only used to treat the organisms listed in the indications. Although the exact mechanism of action against fungi is not known, naftifine appears to interfere with sterol biosynthesis by inhibiting the enzyme squalene 2,3-epoxidase. This inhibition of enzyme activity results in decreased amounts of sterols, especially ergosterol, and a corresponding accumulation of squalene in the cells. Naftifine is used for the topical treatment of tinea pedis, tinea cruris, and tinea corporis caused by the organisms Trichophyton rubrum, Trichophyton mentagrophytes, Trichophyton tonsurans and Epidermophyton floccosum. Marketed as Naftin. — NCATS
Clinical trial activity
16 trials · 7 clinical orgs · 7 marketing orgs
Earliest trial started Sep 1, 2005 (NCT00253305)
Timeline
1980s
- Feb 29, 1988
Earliest FDA Approval
- Feb 29, 1988
Sebela Pharmaceuticals — NDA Secondary Org
- Feb 29, 1988
LEGACY PHARMA — Marketing Organization
1990s
- Jun 18, 1990
Sebela Pharmaceuticals — First NDA Organization
- Jun 18, 1990
Sebela Pharmaceuticals — NDA Organization
2010s
- Jan 1, 2012
Taro Pharmaceuticals — Earliest Phase 1 Sponsor(trial)
- Jan 6, 2016
Taro Pharmaceuticals — Marketing Organization
- Jan 6, 2016
Sun Pharmaceuticals — Marketing Organization
- Apr 10, 2017
Amneal Pharmaceuticals — Marketing Organization
- Apr 10, 2017
Tolmar Inc. — Marketing Organization
2020s
- Sep 22, 2020
Exeltis — Marketing Organization
Indications
Approved for
Mechanism of action
- Squalene monooxygenaseINHIBITOR
Squalene monooxygenase inhibitor
Approval history
- approvedFeb 29, 1988
Chemistry & pharmacology
SMILES
CN(C/C=C/c1ccccc1)Cc1cccc2ccccc12- Mol. weight
- 287.41 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Achiral Molecule
- Inorganic
- No
- Polymer
- No
- Delivery
- Topical
- Availability
- Prescription Only
Oral
No
Parenteral
No
Topical
Yes
Sources
- ChEMBLCHEMBL626 ↗
- WikipediaNaftifine ↗
- NCATS4FB1TON47A ↗
- ChEMBLCHEMBL1200493 ↗
Also known as
- 1-naphthalenemethanamine, n-methyl-n-(3-phenyl-2-propenyl)-, (e)-
- aw-105843
- aw-105843
- aw-105-843
- aw-105-843
- exoderil
- exoderil
- naftifin
- naftifin
- naftifin
- naftifin
- naftifina
- naftifina
- naftifine
- naftifine
- naftifine
- naftifine
- naftifine
- naftifine
- naftifine
- naftifine
- naftifine
- naftifine
- naftifine hcl
- naftifine hcl
- naftifine hcl
- naftifine hydrochloride
- naftifine hydrochloride
- naftifine hydrochloride
- naftifine hydrochloride
- naftifine hydrochloride
- naftifine hydrochloride, (e)-isomer
- naftifinum
- naftifinum
- naftifungin
- naftin
- naftin
- naftin
- naftin
- n-cinnamyl-n-methyl-1-naphthalenemethylamine hydrochloride
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05363449 | Phase 1 | Feb 17, 2022 | Therapeutics, Inc. |
| NCT03897257 | Phase 2 | Mar 15, 2019 | Therapeutics, Inc. |
| NCT02658292 | Phase 2 | Jan 12, 2016 | Merz |
| NCT02633813 | Phase 3 | Mar 1, 2015 | Catawba Clinical Research, Genzum Life Sciences |
| NCT02227290 | Phase 4 | Aug 1, 2014 | Merz |
| NCT02335255 | Phase 1 | Jun 1, 2014 | Catawba Clinical Research, Taro Pharmaceuticals |
| NCT02466867 | Phase 4 | Jan 1, 2014 | Merz |
| NCT02132260 | Phase 1 | Aug 1, 2013 | Catawba Clinical Research, Taro Pharmaceuticals |
| NCT01885156 | Phase 3 | Aug 1, 2013 | Merz |
| NCT01712360 | Phase 4 | Oct 1, 2012 | Merz |
| NCT01580891 | Phase 1 | May 1, 2012 | Taro Pharmaceuticals |
| NCT01290341 | Phase 3 | Feb 1, 2011 | Merz, Paddington Testing Company |
| NCT01289015 | Phase 3 | Feb 1, 2011 | Merz, Paddington Testing Company |
| NCT00750152 | Phase 3 | Sep 1, 2008 | Merz, Paddington Testing Company |
| NCT00750139 | Phase 3 | Aug 1, 2008 | Merz, Paddington Testing Company |
| NCT00253305 | Phase 2 | Sep 1, 2005 | MediQuest Therapeutics |
Organizations
Research & Development (7)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Merz | For profit | 9 | 9 | 3 | 2008 |
| Paddington Testing Company | For profit | 4 | 0 | 1 | 2008 |
| Catawba Clinical Research | For profit | 3 | 0 | 2 | 2013 |
| Taro Pharmaceuticals | For profit | 3 | 3 | 1 | 2012 |
| Therapeutics, Inc. | For profit | 2 | 2 | 2 | 2019 |
| Genzum Life Sciences | For profit | 1 | 1 | 1 | 2015 |
| MediQuest Therapeutics | For profit | 1 | 1 | 1 | 2005 |
Marketing (9)
| Organization | Org type | Relationship | Date |
|---|---|---|---|
| Amneal Pharmaceuticals | For profit | MKTG | Apr 10, 2017 |
| Exeltis | For profit | MKTG | Sep 22, 2020 |
| LEGACY PHARMA | For profit | MKTG | Feb 29, 1988 |
| Sebela Pharmaceuticals | For profit | NDA | Jun 18, 1990 |
| Sebela Pharmaceuticals | For profit | NDA2 | Feb 29, 1988 |
| Sun Pharmaceuticals | For profit | MKTG | Jan 6, 2016 |
| Taro Pharmaceuticals | For profit | MKTG | Jan 6, 2016 |
| Taro Pharmaceuticals | For profit | SYN | Apr 10, 2019 |
| Tolmar Inc. | For profit | MKTG | Apr 10, 2017 |